KR102290592B1 - Her2에 대항하는 적어도 두 개 이상의 반복 도메인을 포함하는 결합 단백질 - Google Patents

Her2에 대항하는 적어도 두 개 이상의 반복 도메인을 포함하는 결합 단백질 Download PDF

Info

Publication number
KR102290592B1
KR102290592B1 KR1020157017376A KR20157017376A KR102290592B1 KR 102290592 B1 KR102290592 B1 KR 102290592B1 KR 1020157017376 A KR1020157017376 A KR 1020157017376A KR 20157017376 A KR20157017376 A KR 20157017376A KR 102290592 B1 KR102290592 B1 KR 102290592B1
Authority
KR
South Korea
Prior art keywords
ala
leu
gly
asp
lys
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020157017376A
Other languages
English (en)
Korean (ko)
Other versions
KR20150091138A (ko
Inventor
윌리케 피들러
이그나시오 돌라도
하이케 스트로벨
Original Assignee
몰리큘라 파트너스 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 몰리큘라 파트너스 아게 filed Critical 몰리큘라 파트너스 아게
Publication of KR20150091138A publication Critical patent/KR20150091138A/ko
Application granted granted Critical
Publication of KR102290592B1 publication Critical patent/KR102290592B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cell Biology (AREA)
KR1020157017376A 2012-11-30 2013-12-02 Her2에 대항하는 적어도 두 개 이상의 반복 도메인을 포함하는 결합 단백질 Expired - Fee Related KR102290592B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12195156.0A EP2738180A1 (en) 2012-11-30 2012-11-30 Binding proteins comprising at least two binding domains against HER2.
EP12195156.0 2012-11-30
PCT/EP2013/075290 WO2014083208A1 (en) 2012-11-30 2013-12-02 Binding proteins comprising at least two repeat domains against her2

Publications (2)

Publication Number Publication Date
KR20150091138A KR20150091138A (ko) 2015-08-07
KR102290592B1 true KR102290592B1 (ko) 2021-08-19

Family

ID=47257683

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020157017376A Expired - Fee Related KR102290592B1 (ko) 2012-11-30 2013-12-02 Her2에 대항하는 적어도 두 개 이상의 반복 도메인을 포함하는 결합 단백질

Country Status (11)

Country Link
US (1) US10370414B2 (enExample)
EP (2) EP2738180A1 (enExample)
JP (1) JP6410724B2 (enExample)
KR (1) KR102290592B1 (enExample)
CN (1) CN104918959A (enExample)
AU (2) AU2013351096C9 (enExample)
CA (1) CA2892747C (enExample)
HK (1) HK1211297A1 (enExample)
MX (1) MX366223B (enExample)
RU (1) RU2664464C9 (enExample)
WO (1) WO2014083208A1 (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI510246B (zh) 2010-04-30 2015-12-01 Molecular Partners Ag 抑制ｖｅｇｆ－ａ受體交互作用的經修飾結合性蛋白質
US9221892B2 (en) * 2010-11-26 2015-12-29 Molecular Partners Ag Capping modules for designed ankyrin repeat proteins
JP2015532306A (ja) * 2012-10-15 2015-11-09 チューリッヒ大学 癌治療のための二重特異性ｈｅｒ２リガンド
JP6486908B2 (ja) 2013-05-31 2019-03-20 モレキュラー パートナーズ アクチェンゲゼルシャフト 肝細胞増殖因子に結合する設計アンキリン反復タンパク質
MX376384B (es) 2013-11-27 2025-03-07 Zymeworks Bc Inc Construcciones de union a antigenos biespecificas dirigidas a her2.
CA2968258A1 (en) 2014-11-27 2016-06-02 Zymeworks Inc. Methods of using bispecific antigen-binding constructs targeting her2
JP6738340B2 (ja) 2015-02-06 2020-08-12 ナフィゴ プロテインズ ゲゼルシャフト ミット ベシュレンクテル ハフツングＮａｖｉｇｏ Ｐｒｏｔｅｉｎｓ ＧｍｂＨ 新規なｅｇｆｒ結合タンパク質
RU2769470C2 (ru) 2015-04-02 2022-04-01 Молекьюлар Партнерс Аг Рекомбинантные связывающие белки и их применение
ES2916101T3 (es) 2015-07-16 2022-06-28 Navigo Proteins Gmbh Nuevas proteínas de unión a inmunoglobulina y su uso en la purificación por afinidad
JP2018520675A (ja) * 2015-07-20 2018-08-02 ナフィゴ プロテインズ ゲゼルシャフト ミット ベシュレンクテル ハフツングＮａｖｉｇｏ Ｐｒｏｔｅｉｎｓ ＧｍｂＨ ジユビキチン変異タンパク質をベースとした新規結合タンパク質及びその生成方法
CA2991814A1 (en) * 2015-07-20 2017-01-26 Navigo Proteins Gmbh Her2 binding proteins based on di-ubiquitin muteins
JP2019526526A (ja) 2016-05-04 2019-09-19 ナフィゴ プロテインズ ゲゼルシャフト ミット ベシュレンクテル ハフツングＮａｖｉｇｏ Ｐｒｏｔｅｉｎｓ ＧｍｂＨ ペプチドリンカーを含む化学的部分の部位特異的カップリングのための標的化合物
RU2627215C1 (ru) * 2016-05-24 2017-08-03 Федеральное государственное автономное образовательное учреждение высшего образования "Национальный исследовательский Нижегородский государственный университет им. Н.И. Лобачевского" Рекомбинантный таргетный токсин, специфичный к клеткам, экспрессирующим рецептор her2
DK3497117T5 (da) 2016-08-11 2024-09-02 Navigo Proteins Gmbh Nye alkalisk stabile immunglobulin-bindende proteiner
CN109790206A (zh) * 2016-09-22 2019-05-21 分子组合公司 重组结合蛋白及其用途
CA3044682A1 (en) 2016-12-02 2018-06-07 University Of Southern California Synthetic immune receptors and methods of use thereof
EP3706804B1 (en) 2017-11-07 2022-02-23 Navigo Proteins GmbH Fusion proteins with specificity for ed-b and long serum half-life for diagnosis or treatment of cancer
MX2021014649A (es) 2019-06-04 2022-01-06 Molecular Partners Ag Dominio de repetición de anquirina diseñado con estabilidad mejorada.
CA3139051A1 (en) 2019-06-04 2020-12-10 Christian REICHEN Multispecific proteins
JP2022535107A (ja) * 2019-06-04 2022-08-04 モレキュラー パートナーズ アクチェンゲゼルシャフト 組換え４－１ｂｂ結合タンパク質及びそれらの使用
EP3980045A1 (en) * 2019-06-04 2022-04-13 Molecular Partners AG Recombinant fap binding proteins and their use
WO2021020846A1 (en) 2019-07-26 2021-02-04 Abl Bio Inc. Anti-her2/anti-4-1bb bispecific antibody and use thereof
CN115003689A (zh) * 2019-12-11 2022-09-02 分子合作伙伴股份公司 具有改变的表面残基的经设计的锚蛋白重复结构域
MX2022013945A (es) 2020-05-06 2023-02-14 Molecular Partners Ag Nuevas proteinas de union a repeticiones de anquirina y sus usos.
JP2023528207A (ja) * 2020-05-14 2023-07-04 モレキュラー パートナーズ アクチェンゲゼルシャフト 組換えｃｄ４０結合タンパク質及びそれらの使用
BR112022023049A2 (pt) 2020-05-14 2022-12-20 Molecular Partners Ag Proteínas multiespecíficas
CA3202358A1 (en) 2020-12-16 2022-06-23 Andreas BOSSHART Novel slow-release prodrugs
EP4304731A1 (en) 2021-03-09 2024-01-17 Molecular Partners AG Novel darpin based multi-specific t-cell engagers
WO2022190008A1 (en) 2021-03-09 2022-09-15 Molecular Partners Ag Protease cleavable prodrugs
CA3211368A1 (en) 2021-03-09 2022-09-15 Molecular Partners Ag Novel darpin based cd123 engagers
CA3211248A1 (en) 2021-03-09 2022-09-15 Nina RESCHKE Novel darpin based cd33 engagers
AU2022413461A1 (en) 2021-12-14 2024-06-06 Molecular Partners Ag Designed repeat domains with dual binding specificity and their use
IL318514A (en) 2022-08-01 2025-03-01 Molecular Partners Ag Loading and using modified re-designed websites
WO2024038307A1 (en) 2022-08-19 2024-02-22 Novartis Ag Dosing regimens for sars-cov-2 binding molecules
WO2024179981A1 (en) 2023-02-27 2024-09-06 Molecular Partners Ag Darpins for use in reducing renal accumulation of drugs
WO2024251628A1 (en) 2023-06-06 2024-12-12 Molecular Partners Ag Recombinant cd16a binding proteins and their use
WO2025146491A1 (en) 2024-01-05 2025-07-10 Molecular Partners Ag Designed repeat domains with dual binding specificity for cd117 and cd47-binding agent

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009068625A2 (en) 2007-11-27 2009-06-04 Ablynx N.V. Amino acid sequences directed against her2 and polypeptides comprising the same for the treatment of cancers and/or tumors

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1997891A1 (en) 1988-09-02 2008-12-03 Dyax Corporation Generation and selection of recombinant varied binding proteins
US5270170A (en) 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method
US5348867A (en) 1991-11-15 1994-09-20 George Georgiou Expression of proteins on bacterial surface
US7371376B1 (en) 1996-10-18 2008-05-13 Genentech, Inc. Anti-ErbB2 antibodies
CA2196496A1 (en) 1997-01-31 1998-07-31 Stephen William Watson Michnick Protein fragment complementation assay for the detection of protein-protein interactions
DE69834032T2 (de) 1997-04-23 2006-12-07 Universität Zürich Verfahren zur erkennung von nucleinsäuremolekülen codierend für (poly)peptide, welche mit zielmolekülen interagieren
ES2280131T3 (es) 1998-12-02 2007-09-01 Adnexus Therapeutics, Inc. Fusiones de adn-proteina y utilizaciones de las mismas.
EP1332209B1 (en) 2000-09-08 2009-11-11 Universität Zürich Collections of repeat proteins comprising repeat modules
WO2005117973A2 (en) * 2004-05-05 2005-12-15 Merrimack Pharmaceuticals, Inc. Bispecific binding agents for modulating biological activity
AU2005287404B2 (en) * 2004-07-22 2009-05-07 Genentech, Inc. HER2 antibody composition
AU2006268780B2 (en) 2005-07-08 2011-03-24 University Of Zurich Phage display using cotranslational translocation of fusion polypeptides
EP1996937A4 (en) 2006-03-06 2009-04-08 Amunix Inc GENETIC PACKS AND USES THEREOF
DE602008005596D1 (de) 2007-06-21 2011-04-28 Univ Muenchen Tech Biologisch aktive proteine mit erhöhter in-vivo- und/oder in-vitro-stabilität
JP2010539915A (ja) 2007-09-24 2010-12-24 ユニバーシティ・オブ・チューリッヒ 設計されたアルマジロリピートタンパク質
US20100260668A1 (en) * 2008-04-29 2010-10-14 Abbott Laboratories Dual Variable Domain Immunoglobulins and Uses Thereof
RU2550258C2 (ru) 2008-11-03 2015-05-10 Молекьюлар Партнерс Аг Связывающие белки, ингибирующие взаимодействия vegf-a рецептора
TW201120210A (en) * 2009-11-05 2011-06-16 Hoffmann La Roche Glycosylated repeat-motif-molecule conjugates
TWI510246B (zh) 2010-04-30 2015-12-01 Molecular Partners Ag 抑制ｖｅｇｆ－ａ受體交互作用的經修飾結合性蛋白質
US9221892B2 (en) 2010-11-26 2015-12-29 Molecular Partners Ag Capping modules for designed ankyrin repeat proteins
EA201391607A1 (ru) 2011-04-29 2014-04-30 Янссен Байотек, Инк. Связывающие il4/il13 белки с повторами и их применение
WO2012162418A1 (en) * 2011-05-23 2012-11-29 The University Of North Carolina At Chapel Hill Methods and compositions for heterodimeric targeting ligands
RU2014150224A (ru) 2012-06-28 2016-08-20 Молекьюлар Партнерс Аг Сконструированный белок с анкириновым повтором, связывающийся с фактором роста тромбоцитов
JP2015532306A (ja) 2012-10-15 2015-11-09 チューリッヒ大学 癌治療のための二重特異性ｈｅｒ２リガンド
JP6486908B2 (ja) 2013-05-31 2019-03-20 モレキュラー パートナーズ アクチェンゲゼルシャフト 肝細胞増殖因子に結合する設計アンキリン反復タンパク質

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009068625A2 (en) 2007-11-27 2009-06-04 Ablynx N.V. Amino acid sequences directed against her2 and polypeptides comprising the same for the treatment of cancers and/or tumors

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Stumpp et al., Current Opinion in Drug Discovery and Development, 10(2), p.153-159 (2007)
Zahnd et al., Journal of Molecular Biology, 369(4), p.1015-1028, (2007)

Also Published As

Publication number Publication date
AU2013351096B2 (en) 2018-08-09
RU2664464C9 (ru) 2018-12-19
AU2018256592A1 (en) 2018-11-22
WO2014083208A8 (en) 2014-10-30
MX2015006548A (es) 2015-10-15
CA2892747A1 (en) 2014-06-05
EP2925784A1 (en) 2015-10-07
JP2015537044A (ja) 2015-12-24
JP6410724B2 (ja) 2018-10-24
RU2015120663A (ru) 2017-01-10
MX366223B (es) 2019-07-03
WO2014083208A1 (en) 2014-06-05
EP2738180A1 (en) 2014-06-04
WO2014083208A9 (en) 2014-12-24
AU2013351096C1 (en) 2018-11-08
US10370414B2 (en) 2019-08-06
RU2664464C2 (ru) 2018-08-17
BR112015012436A2 (pt) 2017-09-12
AU2013351096C9 (en) 2019-01-31
CN104918959A (zh) 2015-09-16
KR20150091138A (ko) 2015-08-07
US20150299265A1 (en) 2015-10-22
EP2925784B1 (en) 2021-02-17
AU2013351096A1 (en) 2015-07-09
HK1211297A1 (zh) 2016-05-20
CA2892747C (en) 2022-07-19

Similar Documents

Publication Publication Date Title
KR102290592B1 (ko) Her2에 대항하는 적어도 두 개 이상의 반복 도메인을 포함하는 결합 단백질
JP6976335B2 (ja) 組み換え結合タンパク質及びその使用
CN108602888B (zh) 抑制癌症生长的结合分子
CN105555804A (zh) 对EGFRvIII有特异性的抗体结合位点
WO2020245173A1 (en) Recombinant fap binding proteins and their use
US20220298212A1 (en) Recombinant 4-1bb binding proteins and their use
US20250074994A1 (en) Novel darpin based cd70 engagers
US20240317852A1 (en) Novel darpin based cd33 engagers
JP2024509241A (ja) 新規のＤＡＲＰｉｎに基づくＣＤ１２３エンゲージャ
KR20210075080A (ko) Her2-결합 사량체 폴리펩티드
CN117242100A (zh) 基于DARPin的新型CD70接合物
RU2778346C2 (ru) Рекомбинантные связывающие белки и их применение
BR112015012436B1 (pt) Proteína de ligação recombinante e formulação farmacêutica
CN116802213A (zh) 重组cd3结合蛋白及其用途
AU2024286934A1 (en) Recombinant cd2 binding proteins and their use
WO2024251742A1 (en) Recombinant cd2 binding proteins and their use
CN117177996A (zh) 基于DARPin的新型CD123接合物

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R15-X000 Change to inventor requested

St.27 status event code: A-3-3-R10-R15-oth-X000

R16-X000 Change to inventor recorded

St.27 status event code: A-3-3-R10-R16-oth-X000

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

A201 Request for examination
AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

X091 Application refused [patent]
T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

PX0701 Decision of registration after re-examination

St.27 status event code: A-3-4-F10-F13-rex-PX0701

X701 Decision to grant (after re-examination)
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R15-X000 Change to inventor requested

St.27 status event code: A-3-3-R10-R15-oth-X000

R16-X000 Change to inventor recorded

St.27 status event code: A-3-3-R10-R16-oth-X000

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20240812

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20240812